Adalimumab (d2e7) (DrugBank: Adalimumab)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
96 | Crohn disease | 1 |
271 | Ankylosing spondylitis | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00055523 (ClinicalTrials.gov) | April 2002 | 4/3/2003 | A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease | A Phase II Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease | Crohn's Disease | Drug: Adalimumab (D2E7) | Abbott | NULL | Completed | 18 Years | 75 Years | Both | 300 | Phase 2 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00085644 (ClinicalTrials.gov) | January 2004 | 10/6/2004 | Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis | A Phase 3 Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis | Ankylosing Spondylitis | Biological: adalimumab (D2E7);Biological: placebo | Abbott | NULL | Completed | 18 Years | N/A | All | 315 | Phase 3 | United States |
2 | NCT00195819 (ClinicalTrials.gov) | December 2003 | 16/9/2005 | Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis | A Phase 3, Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis | Ankylosing Spondylitis | Biological: adalimumab (D2E7);Biological: placebo | Abbott | NULL | Completed | 18 Years | N/A | All | 82 | Phase 3 | Canada;United States |